Maja Zaric, MD
Interventional Cardiology · New York, NYNPI 1922297233
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $12,650 of the $15,931 with a category attached, or 79.4%. Medtronic accounts for 97.6% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2022 at $6,406 and has fallen 98.9% since, to $69 in 2025.
Across 38 payments — averaging $419.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$16K
- Terumo Medical Corporation$149
- Tactile Systems Technology Inc$72
- E.r. Squibb & Sons, L.L.C.$70
- Amgen$68
- Lilly USA, LLC$23
What the payments were for
- Speaking & faculty fees$12,65079%
- Travel & lodging$1,77611%
- Food & beverage$1,5059%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 29 | $15,549 |
| Terumo Medical Corporation | 1 | $149 |
| Tactile Systems Technology Inc | 2 | $72 |
| E.r. Squibb & Sons, L.L.C. | 2 | $70 |
| Amgen | 3 | $68 |
| Lilly USA, LLC | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ClosureFast$11,004
- VenaSeal$3,272
- CoreValve Evolut$190
- COREVALVE EVOLUT R$165
- GlideWire$149
- Misago$149
- TR Band$149
How this compares
$15,931 in reported general payments places this provider in the 60th percentile of 382 interventional cardiology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 48 | $66,921 |
| XareltoRivaroxaban | 32 | $44,885 |
| Praluent PenAlirocumab | 12 | $9,862 |
| Metoprolol Succinate | 96 | $1,284 |
| Nebivolol Hcl | 13 | $1,080 |
| Rosuvastatin Calcium | 82 | $985 |
| Nitroglycerin | 32 | $933 |
| Amlodipine Besylate | 85 | $808 |
| ClopidogrelClopidogrel Bisulfate | 52 | $736 |
| Atorvastatin Calcium | 77 | $716 |
| Amlodipine-ValsartanAmlodipine Besylate/Valsartan | 12 | $480 |
| Lisinopril | 57 | $426 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 17 | $403 |
| Ezetimibe | 12 | $390 |
| Losartan Potassium | 41 | $360 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in New York
- Sahil ParikhNew York$1.6M
- Deepak BhattNew York$1.6M
- Martin LeonNew York$1.5M
- Sripal BangaloreNew York$482K
- Ajay KirtaneNew York$462K
- Prakash KrishnanNew York$387K
- Jaikirshan KhatriNew York$307K
- Samin SharmaNew York$291K
- Torsten VahlNew York$280K
- George DangasNew York$263K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.